Monomethylarsonous acid produces irreversible events resulting in malignant transformation of a human bladder cell line following 12 weeks of low-level exposure.

Arsenic is a known human bladder carcinogen; however, the mechanisms underlying arsenical-induced bladder carcinogenesis are not understood. Previous research has demonstrated that exposure of a nontumorigenic human urothelial cell line, UROtsa, to 50 nM monomethylarsonous acid (MMA(III)) for 52 weeks resulted in malignant transformation. To focus research on the early mechanistic events leading to MMA(III)-induced malignancy, the goal of this research was to resolve the critical period in which continuous MMA(III) exposure (50 nM) induces the irreversible malignant transformation of UROtsa cells. An increased growth rate of UROtsa cells results after 12 weeks of MMA(III) exposure. Anchorage-independent growth occurred after 12 weeks with a continued increase in colony formation when 12-week exposed cells were cultured for an additional 12 or 24 weeks without MMA(III) exposure. UROtsa cells as early as 12 weeks MMA(III) exposure were tumorigenic in severe combined immunodeficiency mice with tumorigenicity increasing when 12-week exposed cells were cultured for an additional 12 or 24 weeks in the absence of MMA(III) exposure. To assess potential underlying mechanisms associated with the early changes that occur during MMA(III)-induced malignancy, DNA methylation was assessed in known target gene promoter regions. Although DNA methylation remains relatively unchanged after 12 weeks of exposure, aberrant DNA methylation begins to emerge after an additional 12 weeks in culture and continues to increase through 24 weeks in culture without MMA(III) exposure, coincident with the progression of a tumorigenic phenotype. Overall, these data demonstrate that 50 nM MMA(III) is capable of causing irreversible malignant transformation in UROtsa cells after 12 weeks of exposure. Having resolved an earlier timeline in which MMA(III)-induced malignant transformation occurs in UROtsa cells will allow for mechanistic studies focused on the critical biological changes taking place within these cells prior to 12 weeks of exposure, providing further evidence about potential mechanisms of MMA(III)-induced carcinogenesis.

[1]  E. Tokar,et al.  Requirement of arsenic biomethylation for oxidative DNA damage. , 2009, Journal of the National Cancer Institute.

[2]  A. J. Gandolfi,et al.  Persistence of DNA damage following exposure of human bladder cells to chronic monomethylarsonous acid. , 2009, Toxicology and applied pharmacology.

[3]  A. J. Gandolfi,et al.  Arsenicals produce stable progressive changes in DNA methylation patterns that are linked to malignant transformation of immortalized urothelial cells. , 2009, Toxicology and applied pharmacology.

[4]  M. Stampfer,et al.  Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. , 2009, Cancer research.

[5]  A. J. Gandolfi,et al.  Epigenetic mediated transcriptional activation of WNT5A participates in arsenical-associated malignant transformation. , 2009, Toxicology and applied pharmacology.

[6]  A. J. Gandolfi,et al.  Reactive oxygen species regulate properties of transformation in UROtsa cells exposed to monomethylarsonous acid by modulating MAPK signaling. , 2009, Toxicology.

[7]  Jie Liu,et al.  Liver is a target of arsenic carcinogenesis. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  Hong Sun,et al.  Arsenite alters global histone H3 methylation. , 2008, Carcinogenesis.

[9]  A. J. Gandolfi,et al.  The role of reactive oxygen species in arsenite and monomethylarsonous acid-induced signal transduction in human bladder cells: acute studies. , 2008, Toxicology.

[10]  A. Devlin,et al.  Hypoxia selects for androgen independent LNCaP cells with a more malignant geno‐ and phenotype , 2008, International journal of cancer.

[11]  T. Jensen,et al.  Epigenetic remodeling during arsenical-induced malignant transformation. , 2008, Carcinogenesis.

[12]  A. J. Gandolfi,et al.  Immortalized human urothelial cells as a model of arsenic-induced bladder cancer. , 2008, Toxicology.

[13]  J. Crawford The origins of bladder cancer , 2008, Laboratory Investigation.

[14]  Jie Liu,et al.  Aberrant DNA methylation and gene expression in livers of newborn mice transplacentally exposed to a hepatocarcinogenic dose of inorganic arsenic. , 2007, Toxicology.

[15]  A. J. Gandolfi,et al.  Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  A. J. Gandolfi,et al.  Monomethylarsonous acid induces transformation of human bladder cells. , 2006, Toxicology and applied pharmacology.

[17]  Soile Tapio,et al.  Arsenic in the aetiology of cancer. , 2006, Mutation research.

[18]  M. Webber,et al.  Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. , 2005, Toxicology and applied pharmacology.

[19]  A. Cress,et al.  Epigenetic silencing of DSC3 is a common event in human breast cancer , 2005, Breast Cancer Research.

[20]  L. Hertle,et al.  Cox-2 and Her2/neu co-expression in invasive bladder cancer. , 2005, International journal of oncology.

[21]  S. Hirohashi,et al.  Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. , 2005, Human molecular genetics.

[22]  A. Sabichi,et al.  Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. , 2005, Cancer research.

[23]  Jie Liu,et al.  Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. , 2004, Carcinogenesis.

[24]  A. J. Gandolfi,et al.  Effects of arsenite on UROtsa cells: low-level arsenite causes accumulation of ubiquitinated proteins that is enhanced by reduction in cellular glutathione levels. , 2004, Toxicology and applied pharmacology.

[25]  S. Garrett,et al.  Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  K. Walen Spontaneous cell transformation: Karyoplasts derived from multinucleated cells produce new cell growth in senescent human epithelial cell cultures , 2004, In Vitro Cellular & Developmental Biology - Animal.

[27]  E. Messing,et al.  DBCCR1 mediates death in cultured bladder tumor cells , 2004, Oncogene.

[28]  P. Scardino,et al.  A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. , 2003, European urology.

[29]  T. Wheeler,et al.  Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. , 2003, The Journal of urology.

[30]  M. Webber,et al.  Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. , 2002, Journal of the National Cancer Institute.

[31]  S. Nesnow,et al.  DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. , 2002, Chemical research in toxicology.

[32]  I. Jaspers,et al.  The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. , 2002, Environmental health perspectives.

[33]  K. G. Brown,et al.  Arsenic, drinking water, and health: a position paper of the American Council on Science and Health. , 2002, Regulatory toxicology and pharmacology : RTP.

[34]  X. Le,et al.  Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid , 2001 .

[35]  N. Altorki,et al.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.

[36]  S. Garrett,et al.  The immortalized UROtsa cell line as a potential cell culture model of human urothelium. , 2001, Environmental health perspectives.

[37]  J. Petrick,et al.  Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. , 2001, Chemical research in toxicology.

[38]  M. Luster,et al.  Quantitative relationship between arsenic exposure and AP-1 activity in mouse urinary bladder epithelium. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  Kazuo T. Suzuki,et al.  Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. , 2001, Chemical research in toxicology.

[40]  S. Nordling,et al.  Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. , 2001, The American journal of pathology.

[41]  M. Knowles,et al.  Hypermethylation at 9q32-33 tumour suppressor region is age-related in normal urothelium and an early and frequent alteration in bladder cancer , 2001, Oncogene.

[42]  W. Cullen,et al.  Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells , 2000, Archives of Toxicology.

[43]  D. Morgan,et al.  Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. , 2000, Chemical research in toxicology.

[44]  L. Keefer,et al.  Induction of proliferative lesions of the uterus, testes, and liver in swiss mice given repeated injections of sodium arsenate: possible estrogenic mode of action. , 2000, Toxicology and applied pharmacology.

[45]  T. Shirahama,et al.  Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  D. E. Carter,et al.  Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. , 2000, Toxicology and applied pharmacology.

[47]  M. Knowles,et al.  Homozygous deletion at the 9q32–33 candidate tumor suppressor locus in primary human bladder cancer , 1999, Genes, chromosomes & cancer.

[48]  D. R. Lewis,et al.  Drinking water arsenic in Utah: A cohort mortality study. , 1999, Environmental health perspectives.

[49]  Patricia A. Elder,et al.  Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. , 1998, Genomics.

[50]  Jiahuai Han,et al.  The Stress Inducer Arsenite Activates Mitogen-activated Protein Kinases Extracellular Signal-regulated Kinases 1 and 2 via a MAPK Kinase 6/p38-dependent Pathway* , 1998, The Journal of Biological Chemistry.

[51]  Andrew J. Dannenberg,et al.  Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[52]  B. Diwan,et al.  Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[53]  T. H. Lin,et al.  Trace element concentration and arsenic speciation in the well water of a Taiwan area with endemic Blackfoot disease , 1995, Biological Trace Element Research.

[54]  M. Vahter Species differences in the metabolism of arsenic compounds , 1994 .

[55]  M. Pike,et al.  Increased cell division as a cause of human cancer. , 1990, Cancer research.

[56]  T. Kuo,et al.  ARSENIC AND CANCERS , 1988, The Lancet.

[57]  J. Monroe,et al.  Sorting of B lymphoblasts based upon cell diameter provides cell populations enriched in different stages of cell cycle. , 1983, Journal of immunological methods.

[58]  T. Saiga,et al.  An improved method for calculating colony forming ability in soft agar with special reference to malignancy , 1981, Experientia.

[59]  H. Seyfert,et al.  Increase in macromolecular amounts during the cell cycle of Tetrahymena: a contribution to cell cycle control. , 1979, Journal of cell science.

[60]  G. Moore,et al.  A transitional cell carcinoma cell line , 1978, In Vitro.

[61]  S. Malik,et al.  Cytogenetic insights into DNA damage and repair of lesions induced by a monomethylated trivalent arsenical. , 2010, Mutation research.

[62]  T. Hei,et al.  Neoplastic Transformation of Human Small Airway Epithelial Cells Induced by Arsenic , 2008, Molecular medicine.

[63]  S. Seshagiri,et al.  Estimation of baculovirus titer based on viable cell size , 2006, Nature Protocols.

[64]  J. Masters,et al.  Immortalisation of human urothelial cells , 2004, Urological Research.

[65]  A. K. Goswami,et al.  Cyclooxygenase-2 Expression Increases with the Stage and Grade in Transitional Cell Carcinoma of the Urinary Bladder , 2004, International Urology and Nephrology.

[66]  T. Rossman,et al.  Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations , 2003, Environmental and molecular mutagenesis.

[67]  Kathleen Shordt,et al.  Arsenic in drinking water. , 2001, Journal of environmental health.

[68]  E. Fosslien Molecular pathology of cyclooxygenase-2 in neoplasia. , 2000, Annals of clinical and laboratory science.

[69]  J. Harman Letter: Realistic goals for smoking and health. , 1974, Lancet.